• Users Online: 272
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 30  |  Issue : 3  |  Page : 154-159

Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis


1 Department of Tropical Medicine and Gastroenterology, Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt
2 Department of Gastroenterology Division, Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt
3 Department of Medical Microbiology and Immunology, Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt
4 Department of Pharmacology, Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt

Correspondence Address:
Dr. Asmaa N Mohammad
17 Abd El-Latif Abo Heggy Street, Sohag City, Sohag, 82515
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejim.ejim_19_18

Rights and Permissions

Background/purpose of the study Spontaneous bacterial peritonitis (SBP) is a cause of significantly higher morbidity and mortality in patients with cirrhosis. This study was conducted to assess the effect of adding rifaximin to cefotaxime in treatment of SBP. Materials and methods The study was a prospective one that involved 98 patients with cirrhosis with SBP, who were divided randomly into two equal groups. Patients in group I received cefotaxime, whereas patients in group II received a combination of cefotaxime and rifaximin. Patients were evaluated clinically, and diagnostic aspiration was repeated on the third day of antibiotic therapy. Results Both groups showed significant reduction in white blood cells on the third day compared with the first day (P<0.0001). Polymorphonuclear leukocyte count in ascetic fluid in both groups showed significant reduction on the third day compared with the first day, and the reduction was statistically significant in group II compared with group I (P<0.0001). One the third day of therapy, serum creatinine levels in group I and group II were 1.61±0.19 and 1.28±0.37, respectively. Both groups showed significant decrease in serum creatinine level. The reduction in group II compared with group I was statistically significant, with P value less than 0.0001. Conclusion Rifaximin plus cefotaxime showed some favorable effects in treatment of SBP than cefotaxime alone. However, the clinical effects of these effects need to be clarified in further studies.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed137    
    Printed0    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal